Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 3021-3026

  Wang, Chih Yuan ^a,b   Zhong, Wen Bin ^a   Chang, Tien Chun ^b   Lai, Shu Mei ^b   Tsai, Yuan Feen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PHOSPHATIDYLSERINE; THYROGLOBULIN; TUMOR NECROSIS FACTOR ALPHA;

ANAPLASTIC THYROID CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SURVIVAL RATE; THYROID CARCINOMA;

APOPTOSIS; CARCINOMA; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICROSCOPY, ELECTRON, SCANNING; PROTEIN ISOPRENYLATION; RADIOIMMUNOASSAY; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0038637313     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021834     Document Type: Article

References (38)

1. Goretzki PE, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M, Horster FA, Roher HD 1993 Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 80:1009-1012
2. Harada T, Kunihiko I, Shimako F 1997 Fatal thyroid carcinoma. Anaplastic transformation of adenocarcinoma. Cancer 39:2588-2596
3. Nesland JM, Sobrinho-Simões M, Johnnessen JV 1987 Scanning electron microscopy of the human thyroid gland and its disorders. Scann Microsc 1:1797-1810
4. Sobrinho-Simões M, Johnnessen JV 1983 A scanning and transmission electron microscopic study of human nodular goiter. Histopathology 7:65-76
5. Weryha G, Marchal L, Leclere J, Grignon G, Hartemann P 1990 Scanning electron microscopy (SEM) of the human thyroid gland: a technical improvement for follicular cell observation. J Submicrosc Cytol Pathol 22:459-464
6. Chang TC, Lai SM, Wen CY, Hsiao YL, Huang SH 2000 Three-dimensional cytomorphology and its relationship with clinical stage in fine needle aspiration biopsy of papillary thyroid carcinoma. Acta Cytol 44:633-639
7. Johnnessen JV, Sobrinho-Simões M 1982 Follicular carcinoma of the human thyroid gland: An ultrastructural study with emphasis on scanning electron microscopy. Diag Histopathol 5:113-127
8. Scandinavian Simvastatin Survival Study Group 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Study Group 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, Cholesterol and Recurrent Events Trial Investigators 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
11. Massy ZA, Keane WF, Kasiske BL 1996 Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 347:102-103
12. Vaughan CJ, Murphy MB, Buckley BM 1996 Statins do more than just lower cholesterol. Lancet 348:1079-1082
13. Guijarro C, Egido J 1997 Modulation of the mevalonate pathway: potential mechanisms of vascular protection independent of cholesterol reduction. Cardiovasc Risk Factors 7:29-33
14. Goldstein JL, Brown MS 1990 Regulation of the mevalonate pathway. Nature 343:425-430
15. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc Natl Acad Sci USA 96:133-138
16. Cox AD, Der CJ 1997 Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophy Acta 1333:F51-F71
17. Park WH, Lee YY, Kim ES, Seol JG, Jung CW, Lee CC, Kim BK 1999 Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res 19:3133-3140
18. Agarwal B, Halmos B, Moss SF, Ramey WG, Holt PR 1998 Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents. Proc Am Assoc Cancer Res 39:68
19. Gray-Bablin J, Rao S, Keyomarsi K 1997 Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57:604-609
20. Weber C, Erl W, Weber PC 1995 Lovastatin induces differentiation of Mono-Mac 6 cells. Cell Biochem Funct 13:273-277
21. Kim JS, Pirnia F, Choi YH, Nguyen PM, Knepper B, Tsokos M, Schulte TW, Birrer MJ 2000 Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 19:6082-6090
22. Maeda T, Matsunuma A, Kawane T, Horiuchi N 2001 Simastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874-877
23. Wang CY, Zhong WB, Chang TC, Lai MS, Tsai YF 2002 Tumor necrosis factor-α induces three-dimensional cytomorphological differentiation of human anaplastic thyroid carcinoma cells via activation of NF-κB. Cancer 95:1827-1833
24. Simon D, Koehrle J, Reiner C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD 1988 Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569-574
25. Hoelting T, Duh QY, Clark OH, Herfarth C 1996 Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 81:2638-2641
26. Schmutzler C, Kohrle J 2000 Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10:393-406
27. Pasca di Magliano M, Di Lauro R, Zannini M 2000 Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97:13144-13149
28. Wächtershäuser A, Akoglu B, Stein J 2001 HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22:1061-1067
29. Yokoyama S, Nozawa F, Mugita N, Ogawa M 1999 Suppression of rat liver tumorigenesis by 25-hydroxycholesterol and all-trans retinoic acid: differentiation therapy for hepatocellular carcinoma. Int J Oncol 15:565-569
30. Grunler J, Ericsson J, Dallner G 1994 Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1212:259-277
31. Goldstein JL, Brown MS 1990 Regulation of the mevalonate pathway. Nature 343:425-430
32. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV 1997 Cdc42 and rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390:632-636
33. Clark E, King WG, Brugge JS, Symons M, Hynes RO 1998 Integrin-mediated signals regulated by members of the Rho family of GTPases. J Cell Biol 142:573-586
34. Zhong WB, Wang CY, Chang TC, Lee WS, Lovastatin can induce apoptosis of anaplastic thyroid cancer cells via inhibition of protein isoprenylation and de novo protein synthesis. Endocrinology, in press
35. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK 2001 Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19:81-83
36. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S 2002 Modulation of inflammatory mediators and PPARgamma and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45:147-154
37. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y, Hato F, Hirakawa K 2002 Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93:1358-1365
38. Berger J, Moller DE 2002 The mechanisms of action of PPARs. Annu Rev Med 53:409-435